NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Mechanism of Action
CLINICAL PHARMACOLOGY Figure 1 Mean (SD) Steady State Darifenacin Plasma Concentration Time Profiles for ENABLEX® 7.5 and 15 mg in Healthy Volunteers Including Both CYP2D6 EMs and PMs* General Darifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role…
Clinical Trials (1)
FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period
Started Jun 2007
9 enrolled
Overactive Bladder